The Study of NT-proBNP Combined With HS-cTnT in Evaluating the Prognosis of Sepsis

NCT ID: NCT04963699

Last Updated: 2021-07-15

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-05-26
• Study Completion Date: 2021-06-09

Brief Summary

To study the clinical value of combined detection of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-cTnT) in assessing the prognosis of patients with sepsis. Methods Seventy-three patients with sepsis who were diagnosed and treated in our hospital from June 2016 to March 2021 were divided into general sepsis group and severe sepsis group. According to different outcomes, they were divided into survival Group and death group, to explore the relationship between plasma NT-proBNP, hs-cTnT levels and APACHEⅡ score and the value of prognostic evaluation of sepsis.

Detailed Description

1.1 Information The 73 patients with sepsis who were diagnosed and treated in our hospital from June 2016 to March 2021 were selected as the research objects. All of them had clear infections through clinical examination; there were no acute coronary syndromes, no immunodeficiency diseases, and no immunodeficiency diseases in the past month. No tumors, etc.; no pulmonary embolism and aortic dissection; no valvular heart disease, cardiomyopathy, myocarditis, etc.; no pregnant women and lactating women; no congenital heart, liver, kidney and other organ diseases. The diagnostic criteria of sepsis refer to the "Guidelines for the Emergency Treatment of Sepsis/Septic Shock in China (2018)" [5]. The patients were divided into general sepsis group (30 cases) and severe sepsis group (43 cases) according to the severity of their illness. The severe sepsis group included severe sepsis (35 cases) and septic shock (8 cases). , Select the population (40 cases) in our hospital for physical examination during the same period as the healthy control group.

1.2 Method 1.2.1 Testing equipment: All patients with sepsis will take 3ml of cubital venous blood when they are admitted to the hospital and place them in a green-head tube containing lithium heparin anticoagulant produced by BD in the United States. After centrifugation at 3000 r/min for 10 minutes, they will be tested immediately; health In the control group, 3ml of cubital venous blood was drawn on an empty stomach in the morning of the physical examination, placed in a lithium heparin anticoagulation tube, centrifuged at 3000 r/min for 10 minutes, and the test was completed within 2 hours. Choose Roche cobas e 601 electrochemiluminescence immunoassay analyzer to detect blood NT-pro BNP and hs-cTnT. Mindray BC 6900 blood cell analyzer detects white blood cell count, Beckman Coulter 5831 automatic biochemical analyzer detects C-reactive protein; all operations are performed in strict accordance with the reagent instructions.

1.2.2 Observation indicators Patients with sepsis undergo acute physiological and chronic health assessment (APACHE II score) within 24 hours after diagnosis.

1.3 Statistical processing SPSS 23.0 software was used for data statistical analysis, measurement data application (x ± s) description, non-parametric test Mann-Whitney U test was used for comparison between groups; plasma NT-proBNP and hs-cTnT were analyzed by rank correlation analysis The correlation between the level and the APACHEⅡ score was analyzed, and the Spearman rank correlation coefficient was used to describe the correlation.

Conditions

Sepsis

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• All have clear infection through clinical examination; no acute coronary syndrome, no immunodeficiency, no tumor, etc. in the past 1 month; no pulmonary embolism or aortic dissection; no valvular heart disease, cardiomyopathy, myocarditis, etc.; no pregnant women And lactating women; no congenital heart, liver, kidney and other organ diseases.

Exclusion Criteria

• Acute coronary syndrome, immunodeficiency, tumor, etc. in the past month; pulmonary embolism and aortic dissection; valvular heart disease, cardiomyopathy, myocarditis, etc.; pregnant and lactating women; congenital Heart, liver, kidney and other organ diseases

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 89 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

yang xufeng, MS

Role: PRINCIPAL_INVESTIGATOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Locations

Roche 601 Biochemical Immunoassay Instrument

Hangzhou, Zhejiang, China

Countries

China

Other Identifiers

2021-0317

Identifier Type: -

Identifier Source: org_study_id